Hola,
Are you new here?

easierNGS

financed

CERTIFIED PACKS FOR EASIER NEXT GENERATION SEQUENCING CLINICAL DIAGNOSTICS

Next-generation sequencing (NGS) has revolutionized genomic research by drastically decreasing the cost of sequencing and increasing the throughput of generated data, but still has not been able to reach its implementation in clin... see more

28/02/2015

STAB VIDA INVESTIG...

71K€

Project Budget: 71K€

Project leader

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2015-02-28

BIOTEC-5a-2014-1: SME boosting biotechnology-based in... Scope:Specific challenge: The large number of SMEs which characterise the EU biotechnology sector ar...

I+D

Cerrada does 10 years

0% 70% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

STAB VIDA INVESTIGACAO E SER...

50.00K€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 5 months Date Start: 2014-09-03
End date: 2015-02-28

Project leader

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 71K€

participation deadline Sin fecha límite de participación.

Project description Next-generation sequencing (NGS) has revolutionized genomic research by drastically decreasing the cost of sequencing and increasing the throughput of generated data, but still has not been able to reach its implementation in clinical diagnostic laboratories where there is a huge potential market application for it. The current market gold-standard in clinical diagnostic (i.e. Sanger-based sequencing) is outdated, much less efficient and more expensive than NGS, but no current market solutions have yet been able to properly address the complexity involved in transferring and validating gold-standard procedures to NGS platforms in clinical environment. In fact, current competing solutions are disruptive, complex, non-efficient and non-validated to address the challenges of transferring NGS to clinics. The easierNGS business concept aims to create and offer an innovative package of services and products which combined will allow a fast, cost-effective, streamlined and certified full sample-to-result solution to clinical laboratories that wish to seize the tremendous benefits of the new NGS era. Towards this objective, a feasibility assessment of the easierNGS business concept will be conducted to better determine its technical, economic and legal viability, as well as plan its most appropriate operational and scheduling strategy. Three case studies (i.e. NGS panels for pharmacogenomics, neonatal screening and infertility risk factors) will be used to generate a proof-of-concept of the easierNGS and help define the technical aspects and guidelines for future easierNGS packages and support a conscientious Go/No go decision towards a real market assessment.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers